A
Alcista
Alcista · 25%ABCL
$2.25
Precio del escenario
$12.370
-0.235 (-1.90%)Al cierre
Loading chart…
- Máximo
- 12.840
- Apertura
- 12.370
- Precio medio ponderado por volumen
- 12.49
- Volumen
- 3.03M
- Capitalización
- 846.88M
- Mínimo
- 12.260
- Importe
- 37.86M
- EV/EBITDA, TTM
- -10.14
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Análisis de IA of AbCellera Biologics Inc. (ABCL)
ComprarAbcellera Biologics Inc is a good buy right now, trading at $12.545 with a forward P/E of 27.55, indicating potential for future earnings growth. The stock has recently seen a significant price target increase from analysts, with JPMorgan setting a target of $17, which represents a 35% upside from the current price. The stock's recent performance includes a year-to-date change of +265.74%, reflecting strong investor interest and momentum. However, the main risk is its negative net income margin of -1368.57%, which indicates ongoing financial challenges that investors should monitor closely.
Métricas de valoración
El PER previsto actual de AbCellera Biologics Inc. (ABCL) es 27.55, frente a su media de 5 años de -0.26.
Escenarios de precio de Alphio AI para ABCL
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ABCL en cartera
Cronología de eventos
Noticias
5.010-01PRnewswireMindWalk Appoints New Director to Enhance Governance
5.010-01NewsfilterMindWalk Appoints New Director to Enhance Governance
7.509-30NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
2.009-30stocktwitsIovance Shares Hit Two-Year High as Revenue Outlook Improves
6.009-29CNBCLatest Wall Street Rating Updates
Preguntas frecuentes sobre ABCL, respondidas por Alphio AI
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Abcellera Biologics Inc is a good buy right now, trading at $12.545 with a forward P/E of 27.55, indicating potential for future earnings growth. The stock has recently seen a significant price target increase from analysts, with JPMorgan setting a target of $17, which represents a 35% upside from the current price. The stock's recent performance includes a year-to-date change of +265.74%, reflecting strong investor interest and momentum. However, the main risk is its negative net income margin of -1368.57%, which indicates ongoing financial challenges that investors should monitor closely.
Comunidad
Más ↗
$ABCL gave you the bottom almost to the penny and the top both days almost on this run from 1.89 to 15.
Mostrar más$ABCL had a phenomenal run from the 2s to 14-15, which is an area of resistance from 2022. More data tomorrow, but I think short term it has run a very nice amount in a short amount of time. A lot of positivity is priced in on VMS. I'm expecting some consolidation or digestion in the 10-15 area, but the thesis is still intact for the long term too, to higher levels like the 20s later if progress and data keep up. If you are an investor, probably stick with it, but if you are a trader, be cautious up here short term.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.